ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,113.59
0.26%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vertex Pharmaceuticals Inc (VRTX)

  7. Vertex Pharmaceuticals Inc (VRTX) Noticias

VRTX Vertex Pharmaceuticals Inc

445.21
4.57 (1.04%)
17 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vertex Pharmaceuticals Inc VRTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
4.57 1.04% 445.21 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
442.00 440.33 446.10 445.21 440.64
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
17/5/202415:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202415:16EDGAR2Form 3 - Initial statement of beneficial ownership of..
16/5/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202411:20EDGAR2Form 144 - Report of proposed sale of securities
15/5/202410:50EDGAR2Form 144 - Report of proposed sale of securities
15/5/202410:41EDGAR2Form 144 - Report of proposed sale of securities
15/5/202409:30BWJennifer Schneider Elected to Vertex Board of Directors
10/5/202407:01EDGAR2Form SC TO-T/A - Tender offer statement by Third Party:..
08/5/202407:54EDGAR2Form SC TO-T/A - Tender offer statement by Third Party:..
07/5/202415:14EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202406:46IHMARKETNEWSDisney Slashes Streaming Losses, UBS shoots up 9% as profit..
06/5/202415:03EDGAR2Form 8-K - Current report
06/5/202415:01BWVertex Reports First Quarter 2024 Financial Results
06/5/202407:09IHMARKETNEWSIndex Futures Point to Strong Monday Opening, Building on..
26/4/202410:43BWVertex Announces European Commission Approval for KALYDECO®..
22/4/202423:45PRNCAVERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING..
18/4/202407:00BWVertex Announces Advancements of Suzetrigine (VX-548) in..
11/4/202406:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
10/4/202415:01BWVertex Enters Into Agreement to Acquire Alpine Immune..
09/4/202415:05BWVertex to Announce First Quarter 2024 Financial Results on..
01/4/202410:00PRNCAVertex Announces New Drug Submission for Exagamglogene..
01/4/202407:00BWVertex Advances Inaxaplin (VX-147) into Phase 3 Portion of..
21/3/202407:00BWVertex Announces FDA Clearance of Investigational New Drug..
27/2/202416:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202416:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202412:19EDGAR2Form 144 - Report of proposed sale of securities
26/2/202410:25EDGAR2Form 144 - Report of proposed sale of securities
26/2/202410:10EDGAR2Form 144 - Report of proposed sale of securities
26/2/202409:52EDGAR2Form 144 - Report of proposed sale of securities
26/2/202409:44EDGAR2Form 144 - Report of proposed sale of securities
26/2/202409:26EDGAR2Form 144 - Report of proposed sale of securities
23/2/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202406:10BWVertex Receives CHMP Positive Opinion for KALYDECO® for the..
21/2/202415:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202415:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Su Consulta Reciente

NASDAQ
VRTX
Vertex Pharmaceuticals
LSE
0EL9
Geratherm Medical
NYSE
SN
Sharkninja
NYSE
CMC
Commercial Metals
TSX
TVK
TerraVest Industries
EU
LSP
LSP Life Sciences Fund NV
LSE
KAY
Kings Arms Yard Vct
AMEX
ELLO
Ellomay Capital
LSE
BREE
Breedon
LSE
0IAK
Sirma Ad
NYSE
ELP
Companhia Parana De Energ
FX
USDAMD
US Dollar vs AMD
TSX
CRON
Cronos
NYSE
CV
Central Vermont Public Service
ASX
KNBNA
Koonenberry Gold
NYSE
PPL
PPL
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados